Cadila Healthcare has reported results for first quarter ended June 30, 2012.
On standalone basis, the company has reported a fall of 13.23% in its net profit at Rs 132.70 crore for the quarter, as compared to Rs 152.93 crore for the same quarter in the previous year. However, total income of the company has increased by 4% to Rs 822.11 crore for the quarter under review as compared to Rs 790.52 crore for the quarter ended June 30, 2011.
On consolidated basis, the company has reported a fall of 15.24% in its net profit at Rs 194.79 crore for the quarter, as compared to Rs 229.82 crore for the same quarter in the previous year. However, total income of the company has increased by 28.11% to Rs 1603.93 crore for the quarter under review as compared to Rs 1252.00 crore for the quarter ended June 30, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1686.70 |
| Dr. Reddys Lab | 1215.55 |
| Cipla | 1228.40 |
| Zydus Lifesciences | 937.95 |
| Lupin | 2323.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: